New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Go back to New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 286.41 +8.32 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $278.09 | 52 Week High | $109.10 | |||
| Open | $278.42 | 52 Week Low | $31.38 | |||
| Day High | $286.67 | P/E | N/A | |||
| Day Low | $278.17 | EPS | $-1.45 | |||
| Volume | 1,420,698 | |||||
